TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
The American Geriatrics Society has published a case-based framework for clinicians prescribing obesity medications to older adults. It applies the Geriatrics 5Ms to treatment decisions and stresses assessing function, nutrition and cognition, with attention to muscle loss, frailty and dehydration. The framework is guidance; the source report does not provide new clinical trial results or establish that the approach improves outcomes.
The American Geriatrics Society (AGS) has published a case-based framework to help clinicians make patient-centered decisions about obesity medications in older adults, including GLP-1 medicines. The guidance calls for evaluating functional ability, nutrition and cognition before treatment, reflecting concerns about frailty, muscle loss and other age-related risks in a group that has been underrepresented in clinical trials.
The paper, developed by the AGS Healthy Aging Special Interest Group, was published in the Journal of the American Geriatrics Society. It applies the AGS Geriatrics 5Ms Framework—Mind, Mobility, Medications, Multicomplexity and Matters Most—to incretin therapy in older adults. Rather than offering a single prescribing rule, the authors organize the discussion around clinical cases to help clinicians weigh treatment choices in light of individual circumstances and priorities.
The framework recommends a pretreatment assessment of functional status, nutritional adequacy and cognitive impairment. The report highlights possible concerns including sarcopenia and frailty, loss of lean muscle, malnutrition and dehydration. It also notes that obesity medicines may offer benefits for weight management, glycemic control and other health conditions; those potential benefits need to be weighed against an older patient’s health status and care goals.
The authors say prescribing may need to be paired with resistance training and adequate dietary protein. For some patients, care may involve a team that includes a registered dietitian, physical therapist, fitness trainer and behavioral health professional. The paper is Elias M. Wisdom and colleagues’ “Obesity Medications in Older Adults: A Geriatrics 5Ms Framework for Safe and Patient-Centered Prescribing,” DOI 10.1111/jgs.70769.
Balancing Weight Treatment With Function
The framework addresses a practical challenge for clinicians: decisions about obesity medicines in later life may involve more than weight or blood sugar. Mobility, muscle strength, nutrition and cognitive status can affect how a treatment fits into a person’s overall care, and the paper encourages clinicians to consider those factors before prescribing.
This matters because the report says older adults are underrepresented in clinical trials of these medications. That limits how directly trial evidence may answer questions about use in older patients, particularly those with frailty or multiple health conditions. The framework offers a structured way to discuss risks, possible benefits and patient priorities, but it is not itself evidence that a particular medicine or co-intervention will produce a specific outcome.
Its emphasis on individualized assessment may also affect follow-up and care coordination. If treatment is chosen, clinicians may need to monitor nutrition and physical function and consider whether additional support is appropriate. The source describes these as prescribing considerations, not a universal requirement for every patient.
Products Worth Considering
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
Bowflex SelectTech 840 Adjustable Kettlebell
TheraGun Therabody PRO Plus 6-in-1 Deep Tissue Massage Gun, Black
As an affiliate, we earn on qualifying purchases.
Applying the Geriatrics 5Ms
The 5Ms framework organizes older-adult care around Mind, Mobility, Medications, Multicomplexity and Matters Most. In this paper, the AGS group uses those areas to examine incretin-based obesity therapy through clinical cases. The approach gives clinicians a way to connect medication decisions with cognition, movement, other medicines, complex health needs and what matters to the patient.
The report specifically includes GLP-1 medications, which act through gut-derived hormonal pathways, within its discussion of obesity medicines. It describes potential benefits for weight management and glycemic control while highlighting the need to account for risks that may be especially relevant in older adults. The article does not name a particular product or set out a medication-by-medication comparison in the supplied summary.
The framework was published in the Journal of the American Geriatrics Society in 2026. The available report summarizes its recommendations but does not provide detailed case outcomes, prescribing rates or evidence from a trial testing the framework itself.
“The paper applies the Geriatrics 5Ms Framework—Mind, Mobility, Medications, Multicomplexity and Matters Most—to incretin therapy in older adults.”
— Elias M. Wisdom and colleagues, authors of the paper
Evidence Gaps in Older Patients
The supplied report does not specify how many older adults were included in the clinical trials discussed, or provide age-specific estimates of benefits and harms. It also does not report results from a trial evaluating whether use of the 5Ms framework changes prescribing decisions or patient outcomes. Those details should not be inferred from the publication’s recommendations.
It remains unclear from the summary how the authors advise clinicians to adapt treatment for particular combinations of frailty, cognitive impairment, malnutrition or other conditions. The framework’s case-based discussion may address such situations in the full paper, but the source material does not reproduce those case details. The report also does not identify a specific monitoring schedule, dose strategy or threshold for discontinuing medication.
The source presents resistance training, sufficient dietary protein and possible team-based care as considerations, not as a prescription that applies identically to every older adult. Decisions still depend on the individual’s clinical circumstances and priorities.
How Clinicians May Use the Guidance
The paper is available in the Journal of the American Geriatrics Society, where clinicians can consult the full case-based discussion and its application of the 5Ms. The AGS framework is intended to inform clinical decision-making; the supplied report does not announce a rollout, formal implementation timetable or subsequent evaluation.
For patients and clinicians, the immediate practical step described in the paper is a conversation before treatment about function, nutrition, cognition and personal goals, alongside potential benefits and risks. If medication is selected, the report points to resistance exercise, adequate protein intake and coordination with relevant professionals as possible components of care. How these recommendations are adopted in practice, and whether they improve outcomes, remains to be established.
Key Questions
Who issued the new prescribing framework?
The American Geriatrics Society developed the paper through its Healthy Aging Special Interest Group. It was published in the Journal of the American Geriatrics Society.
Which medications does the framework discuss?
It addresses obesity medications, including incretin therapies such as GLP-1 medicines. The source summary does not provide a product-by-product comparison.
What should clinicians assess before prescribing?
The paper recommends assessing functional status, nutritional adequacy and cognitive impairment, while considering issues such as frailty, sarcopenia, lean muscle loss, malnutrition and dehydration.
Does the framework require exercise or dietitian support for every patient?
No universal requirement is stated in the source summary. The authors recommend considering resistance training and adequate dietary protein; some older adults may benefit from a team-based approach that includes nutrition, physical therapy or behavioral health professionals.
Does the paper prove that the framework improves outcomes?
The supplied report describes a clinical framework and its recommendations, not a trial testing whether the framework improves patient outcomes. Its effect on outcomes remains unclear from the available information.
Source: medicalxpress.com
